Intellia Therapeutics, Inc. filings document the business, governance and capital structure of a Nasdaq-listed clinical-stage biopharmaceutical company developing CRISPR-based therapies. Its Form 8-K reports record quarterly financial results and business updates, clinical and regulatory disclosures for lonvo-z in hereditary angioedema, nex-z in ATTR amyloidosis, and related FDA communications.
The filing record also includes common stock financing disclosures, including an underwritten public offering and amendments to an at-the-market sales program. Proxy materials describe annual meeting matters, executive compensation, equity awards and board governance, while bylaw amendments and other corporate filings address shareholder proposal procedures, forum provisions and registered common stock listed on The Nasdaq Global Market.
Intellia Therapeutics, Inc. (NTLA) reported third-quarter collaboration revenue of $7.2 million, down from $13.8 million a year earlier, and a net loss of $127.5 million, versus $101.3 million. Nine-month revenue was $29.9 million versus $44.7 million; operating cash used was $285.9 million versus $325.5 million.
The FDA accepted lonvo-z’s BLA and granted Priority Review, with a PDUFA target action date of March 10, 2027. In Phase 3 HAELO, a one-time infusion reduced HAE attacks 87% versus placebo during weeks 5–28; 62% of lonvo-z patients were entirely attack-free and therapy-free versus 11% on placebo. Intellia’s initial draw was $75 million under a five-year senior secured facility of up to $400 million; potential additional term loans are tied to FDA approval, revenue or equity-fundraising milestones.
The FDA lifted clinical holds on both nex-z Phase 3 trials in 2026. An analysis of more than 600 patient samples found the highest observed liver transaminase elevations in patients carrying one specific HLA allele; Intellia said it would provide genotyping results for enrolled and screening patients while engaging with the FDA.
Intellia Therapeutics, Inc. (NTLA) reported a third-quarter 2026 net loss of $127.5 million, compared with $101.3 million a year earlier. Collaboration revenue was $7.2 million versus $13.8 million; research and development expense was $83.3 million versus $94.7 million, while general and administrative expense rose to $46.1 million from $30.5 million.
Cash, cash equivalents and marketable securities totaled $614.8 million as of September 30, 2026. Intellia expects existing cash resources to fund operations at least into 2028, excluding potential lonvo-z commercial revenue and future term-loan funding. FDA accepted lonvo-z’s BLA and granted Priority Review, with a March 10, 2027 target action date; Intellia is preparing for a planned first-quarter 2027 commercial launch. Intellia completed MAGNITUDE-2 Phase 3 enrollment in ATTRv-PN, exceeding the 60-patient target, and advanced enrollment in MAGNITUDE for ATTR-CM.
Intellia Therapeutics, Inc. President and CEO John M. Leonard sold 9,000 shares of common stock on November 2, 2026, at a weighted average price of $11.99 per share. The shares were sold automatically under a Rule 10b5-1 trading plan adopted on May 21, 2026; individual sale prices ranged from $11.65 to $12.60. After the sale, Leonard held 1,138,064 shares directly. A separate holding row lists 58,415 shares held by the John M. Leonard 2015 Irrevocable Trust.
Intellia Therapeutics, Inc. officer and director John M. Leonard reported a proposed sale of 9,000 common shares through UBS Financial Services, Inc., with an approximate aggregate market value of $113,400.00 and an approximate sale date of November 2, 2026. Leonard acquired the shares through an issuer stock-option exercise on February 9, 2021. The notice also lists sales of 19,890 shares for $250,683.26 on August 20, 2026, and 2,789 shares for $36,205.00 on August 21, 2026.
Intellia Therapeutics, Inc. (NTLA) reported that Jing L. Marantz, EVP, Chief Medical Officer, received 199,822 restricted stock units, each representing a contingent right to receive one common share, and options covering 275,061 common shares on October 26, 2026. The options have an $11.26 exercise price and expire October 25, 2036.
Intellia Therapeutics, Inc. (NTLA) VP, Chief Accounting Officer Michael P. Dube reported a sale of 1,864 common shares at $12.43 per share on October 2, 2026. The transaction was a mandatory sell-to-cover for tax withholding on RSUs that vested October 1, 2026, and did not represent a volitional trade. Dube directly held 65,022 shares afterward. No Rule 10b5-1 plan is reported.
Intellia Therapeutics, Inc. officer Eliana Clark gave notice of a proposed sale of 57,750 common shares, with an aggregate market value of $736,312.50. The notice lists Morgan Stanley Smith Barney LLC as broker, Nasdaq as the exchange, and October 5, 2026, as the approximate sale date. It lists the shares as acquired from the issuer through a stock option exercise for cash on October 5, 2026.
Intellia Therapeutics, Inc. (NTLA) reports that the U.S. FDA has accepted its Biologics License Application for lonvoguran ziclumeran (lonvo-z) for hereditary angioedema and granted Priority Review with a Prescription Drug User Fee Act target action date of March 10, 2027. FDA also indicated it is not currently planning to hold an advisory committee meeting on the application. The BLA is supported by a global Phase 3 HAELO trial of 80 patients, where a single 50 mg dose of lonvo-z achieved an 87% reduction in mean monthly attacks versus placebo and 62% of treated patients were attack-free and HAE-therapy-free over six months. All treatment-emergent adverse events in the lonvo-z arm were mild or moderate with no serious adverse events reported. Intellia highlights that, if approved, lonvo-z could become the first in vivo CRISPR-based therapy and the only one-time treatment for HAE.
Intellia Therapeutics, Inc. (NTLA) entered into a senior secured Credit Agreement with OrbiMed-affiliated lenders providing a five-year credit facility of up to $400 million. An initial $75 million was drawn at closing, with additional tranches tied to regulatory, revenue and equity fundraising milestones, plus an uncommitted $100 million incremental option.
The facility matures on September 4, 2031. Loans bear monthly interest at the one-month SOFR (with a 3.00% floor) plus a 6.15% margin, implying a minimum annual rate of 9.15%, plus customary fees. Obligations are secured by first‑priority liens on substantially all company assets, including intellectual property, and are subject to mandatory prepayments from certain debt financings, asset sales and casualty proceeds.
Covenants include maintaining at least $50 million of liquidity in controlled accounts until FDA approval of the BLA for lonvoguran ziclumeran (lonvo‑z), and thereafter satisfying revenue, market capitalization or cash-balance tests. Negative covenants restrict additional debt, liens, M&A, asset sales, licensing and dividends, while permitting certain synthetic royalty transactions. Proceeds are for working capital and general corporate purposes.